biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 6/2025 | 03-04-2025 | Decyzja Zarządu dotycząca procesu certyfikacji FDA dla systemu BACTEROMIC

Previous PostRAPORT ESPI 5/2025 | 28-02-2025 | Rozszerzenie współpracy z BIT w ramach projektu BACTEROMICNext PostRAPORT ESPI 7/2025 | 23-04-2025| Decyzja Zarządu dotycząca wniosku do ZWZ dotyczącego podziału zysku za 2024 rok

0Shares

Related Posts

Scope Fluidics signs agreement for distribution of the BACTEROMIC system in 10 European markets

SCOPE FLUIDICS0

Scope Fluidics Signs Agreement for Clinical Trials of the BACTEROMIC System PBC Panel

SCOPE FLUIDICS0

Scope Fluidics Secures New Location for Semi-Automated BACTEROMIC Panel Production Line

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved